Is routine rotavirus vaccination recommended for infants in Central Europe?

Rotavirus Vaccination in Central Europe

Yes, routine rotavirus vaccination is strongly recommended for all infants in Central Europe, despite the lack of uniform national recommendations in most countries in this region.

Current Situation in Central Europe

The evidence clearly demonstrates a significant disease burden in Central Europe that warrants universal vaccination:

• Rotavirus remains the leading cause of acute gastroenteritis requiring hospitalization in children under 5 years across Central European countries 1
• Each year, rotavirus causes substantial morbidity, yet inadequate surveillance systems and lack of routine testing make it difficult to accurately assess the full burden 1
• Most Central European countries lack official recommendations and have not implemented routine immunization programs, despite the available evidence supporting vaccination 1

Evidence Supporting Universal Vaccination

Vaccine Efficacy and Effectiveness

The vaccines demonstrate exceptional protection against severe disease:

• Rotavirus vaccines are 85-98% protective against severe rotavirus disease and 74-87% protective against disease of any severity 2
• Vaccine effectiveness against hospitalization is 92%, with 91% efficacy against severe rotavirus-associated gastroenteritis in settings comparable to Central Europe 3
• Protection increases with disease severity: 59% against mild disease, 80% against moderately severe disease, and 94% against very severe disease 4

Impact on Healthcare Systems

Vaccination provides substantial benefits beyond individual protection:

• Herd immunity effects protect unvaccinated age groups, with demonstrated decreases in nosocomial rotavirus infections after vaccine introduction 3
• Rotavirus vaccination reduces healthcare resource utilization and related costs in both vaccinated subjects and unvaccinated siblings through herd protection 5
• Prevention of 75,000-150,000 hospitalizations annually could be achieved across Europe with universal vaccination programs 6

Safety Profile

The vaccines have an acceptable safety profile:

• The risk-benefit ratio is strongly positive, with only a slightly increased risk of intussusception shortly after the first dose 3
• The absolute risk is minimal: 1-2 additional intussusception cases per 100,000 infants vaccinated (relative risk 1.21,95% CI 0.68-2.14) 3
• Long-term surveillance indicates no overall increase in intussusception, and increasing evidence suggests an overall reduction in intussusception in the first 12 months of life when early, high vaccine coverage is achieved 6

Vaccination Schedule

Two vaccines are available with different schedules:

• RV5 (RotaTeq): 3-dose series at 2,4, and 6 months of age 2
• RV1 (Rotarix): 2-dose series at 2 and 4 months of age 2

Critical Timing Requirements

• First dose must be administered between 6 weeks and 14 weeks, 6 days of age 2
• Minimum interval between doses is 4 weeks 2
• All doses must be completed by 8 months, 0 days of age 2

Rationale for Universal Rather Than Targeted Vaccination

Universal vaccination is superior to risk-group-only strategies:

• Most rotavirus mortality affects previously healthy infants, not children from identifiable risk groups 7
• There is no accountable evidence of increased severity in specific risk groups, including preterm or immunocompromised children 7
• Identifying all high-risk infants within the first few weeks of life is difficult, especially in countries without primary care pediatricians, and incurs additional costs 7
• Universal immunization in areas with large coverage has greatly improved child health, reducing infection rates, hospitalization, and costs 7

Economic Considerations

The cost-effectiveness supports implementation:

• Cost-effectiveness and cost-saving benefits justify greater access to rotavirus vaccines for infants living in Europe 5
• Prevention has marked positive impacts on parental wages and government tax revenue, with benefits extending across the whole economy 6
• Rotavirus case-fatality is extremely low in Germany (representative of Central Europe), but incidence is high (8-14 cases per 1,000 children annually), with almost half requiring hospitalization 3

Common Pitfalls to Avoid

• Do not delay vaccination initiation: The first dose must be given before 15 weeks of age due to insufficient safety data in older infants 2
• Do not defer vaccination for minor illnesses: Rotavirus vaccine can be administered to infants with mild gastroenteritis or upper respiratory infections 2
• Do not withhold vaccination from breastfed infants: Vaccine efficacy is similar among breastfed and nonbreastfed infants 2
• Do not restrict feeding before or after vaccination: No feeding restrictions are necessary 2

Implementation Recommendation

Central European countries should implement universal rotavirus vaccination programs for all infants, following the established schedules, with the primary goal of preventing rotavirus-associated hospitalizations, especially among infants and young children 3. The main barrier to implementation is lack of awareness among stakeholders, policymakers, healthcare professionals, and parents about rotavirus disease burden and vaccination advantages 8. Addressing this awareness gap is essential for successful implementation 8.